Early phase II dose-finding study of exemestane in postmenopausal patients with advanced/recurrent breast cancer

Toshio Tabei, Masami Ogita, Kouichi Hirata, Susumu Satomi, Michio Kimura, Rikiya Abe, Yasuo Morishita, Morihiko Kimura, Jirou Andou, Yasuhiro Higashi, Keiichi Yoshino, Ken Tominaga, Tetsuro Kajiwara, Masaki Kitajima, Yasuhisa Koyanagi, Toru Watanabe, Susumu Yamaguchi, Mamoru Watanabe, Kazushige Toyama, Kazuhiro KandaYoshitomo Kashiki, Shigeto Miura, Zhunzo Kobayashi, Hideaki Aoyama, Itsuo Miyazaki, Takahiro Oka, Hiroki Koyama, Hiroaki Kinoshita, Morito Monden, Shinichiro Takai, Eiji Yayoi, Tetsuo Kobayashi, Yuichi Takatsuka, Tatehiro Kajiwara, Hiroshi Sonoo, Tesuya Toge, Shigemitsu Takashima, Yasuo Nomura, Kazuharu Nagao, Yoshie Fujita

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)


Exemestane was administered orally to postmenopausal women with advanced/recurrent breast cancer at a dose of 10 mg/day or 25 mg/day once daily for more than 8 weeks in order to evaluate the drug's anti-tumor effects and safety in a dose-finding study. The response rate (CR + PR) in the 10 mg and 25 mg group was 25.0% (8/32) and 31.4% (11/35), respectively, demonstrating no significant differences between the two groups, yet a higher efficacy rate was observed in 25 mg group. The efficacy rate in hormone-treatment-resistant patients within the 10 mg and 25 mg groups was 14.3% (3/21) and 26.1% (6/23), respectively, demonstrating more than a 20% response rate in 25 mg group. Incidences of the adverse events of which relevance to the drug could not be excluded were 30.6% (11/36) in the 10 mg group. 13.9% (5/36) in the 25 mg group and 22.2% (16/72) in the total group. The major adverse events were, hot flashes, numbness of the limbs, nausea, headache etc. Abnormal findings in clinical laboratory tests were as follows: ALP increase; GOT increase; GPT increase; gamma-GTP increase; total cholesterol increase; urinary sediment present. Abnormal findings in endocrine function were as follows: aldosterone decrease; testosterone.cortisol.DHEA-S decrease. But discontinuation due to abnormal laboratory findings was not found. No abnormal findings in physical tests were observed. A significant decrease in plasma estrogen concentration at week 4 was observed in both the 10 mg and 25 mg groups compared with baseline. These low levels were maintained throughout the study period. On the basis of these results, the efficacy of exemestane 25 mg/day was verified to be slightly higher than 10 mg/day. In addition the safety profile had no major adverse events to notice. In these patients with advanced/recurrent breast cancer, 25 mg/day was recommended as the most appropriate dose to be used clinically.

Original languageEnglish
Pages (from-to)1199-1209
Number of pages11
JournalGan to kagaku ryoho. Cancer & chemotherapy
Issue number7
Publication statusPublished - 2002 Jul
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Early phase II dose-finding study of exemestane in postmenopausal patients with advanced/recurrent breast cancer'. Together they form a unique fingerprint.

Cite this